Zymeworks' (ZYME) drug to treat certain reproductive tract cancers has shown promise in early testing, the biotechnology company reported Sunday at the European Society for Medical Oncology Gynaecological Cancers Congress.
The dose-escalation portion of an ongoing phase 1 study showed ZW191, an antibody-drug conjugate, achieved a 78.6% response rate in patients with high levels of the target protein, compared to 47.4% in patients with low or negative levels.
The results further support the potential of ZW191 to address limitations of currently available and investigational therapies and broaden treatment opportunities for patients with gynecologic cancers, said Zymeworks.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.